Sangamo Therapeutics, Inc.Equity-NMS: SGMO
Equity-NMS: SGMO
$0.6
-0.02
(27 May)
Loading Chart
1D
1W
3M
1Y
5Y
Previous close
$0.60
Open
$0.60
Today’s high
$0.63
Today’s low
$0.57
52W low
$0.29
52W high
$1.67
1Y
-52.38%
5Y
-42.64%
PE
-0.39
EPS (TTM)
-1.85
Shares O/S
207.51M
Market cap
124.51M
Insights
SGMO is in the lowest 10% returns in the past year. It is a low momentum stock. Low momentum stocks tend to underperform in the near term.
In beta. Send feedback here.
Compare with other stock
Price
1D
PE
Market cap
About Sangamo Therapeutics, Inc.

Sangamo Therapeutics, Inc. is a genomic medicines company that is developing medicines for neurological diseases. The Company's neurology preclinical development is focused on two areas: development of epigenetic regulation therapies to treat serious neurological diseases, and development of novel engineered adeno-associated virus (AAV) capsids to deliver its therapies to the intended neurological targets.

The Company's zinc finger epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid discovery platform is expanding delivery beyond intrathecal delivery capsids, including in the central nervous system. Its clinical-stage product candidates are Isaralgagene civaparvovec, also known as ST-920, its wholly-owned gene therapy product candidate for the treatment of Fabry disease, and TX200, its wholly-owned CAR-Treg cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation. .


FAQs

Can I buy Sangamo Therapeutics, Inc. shares in India?
How to buy Sangamo Therapeutics, Inc. shares in India?
What is the share price of Sangamo Therapeutics, Inc.?
What is the Market Capitalization of Sangamo Therapeutics, Inc.?
What is the PE ratio of Sangamo Therapeutics, Inc.?
Is Sangamo Therapeutics, Inc. a good stock to buy?
In which sector / industry does Sangamo Therapeutics, Inc. operate?